Author

Grace S. Park

Observed names: Grace S Park, Grace S Park-West

Institutions: Tulane University, AbbVie (United States)

Observed institutions: Tulane University, AbbVie (United States)

OpenAlex ID: A5070404543

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

2023 · Quentin M. Anstee, Brent A. Neuschwander-Tetri, et al. · Clinical Gastroenterology and Hepatology · 180

Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial

2024 · Sabrina Fabi, Shannon Humphrey, et al. · Journal of the American Academy of Dermatology · 21

Improving Neck and Jawline Aesthetics With OnabotulinumtoxinA by Minimizing Platysma Muscle Contraction Effects: Efficacy and Safety Results in a Phase 3 Randomized, Placebo-Controlled Study

2024 · Sachin M Shridharani, Patricia Ogilvie, et al. · Aesthetic Surgery Journal · 19

Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis

2024 · Sven M. Francque, Alexander Hodge, et al. · Hepatology Communications · 16

Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study

2024 · Rod J. Rohrich, Vince Bertucci, et al. · Plastic & Reconstructive Surgery · 14

Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Glabellar Lines: A Phase 2b, Double-Blind, Placebo-Controlled, Dose-Escalation Study

2026 · Edward Lain, Leslie Baumann, et al. · Aesthetic Surgery Journal · 4

Rapid Results With TrenibotulinumtoxinE for the Treatment of Glabellar Lines in Toxin-Naive Adults: Safety, Efficacy, and Satisfaction Findings From a Pivotal Phase 3 Study

2026 · Edward Lain, Rosalyn George, et al. · Aesthetic Surgery Journal · 2

54237 Treating Platysma Prominence with OnabotulinumtoxinA: Safety and Efficacy Results from a Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled Study

2024 · Sabrina Fabi, Brian Biesman, et al. · Journal of the American Academy of Dermatology · 2

54285 Evaluating the Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Platysma Prominence: Results from a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

2024 · Sachin M. Shridharani, Megan Couvillion, et al. · Journal of the American Academy of Dermatology · 1

Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis

2020 · Naim Alkhouri, Vincent Wai-Sun Wong, et al. · Journal of Hepatology · 1

Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 Studies

2026 · Patricia Ogilvie, William P Coleman, et al. · Aesthetic Surgery Journal

OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study

2025 · Deanne Mraz, C. William Hanke, et al. · Plastic & Reconstructive Surgery

Works count: 12

Citation count: 260

H-index: 5

I10-index: 5